Harmony Biosciences Holdings (HRMY) Cash & Equivalents (2019 - 2026)

Harmony Biosciences Holdings has disclosed Cash & Equivalents across 8 years of filings, most recently posting $589.4 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $589.4 million, up 39.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $589.4 million (up 39.21% YoY), and the FY2025 annual result was $752.5 million, up 66.11% from the prior year.
• Cash & Equivalents came in at $589.4 million for Q1 2026 at Harmony Biosciences Holdings, down from $752.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $752.5 million in Q4 2025 to a low of $224.5 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $333.0 million (2024), against an average of $394.5 million.
• Across the five-year window, Cash & Equivalents jumped 82.98% in 2022 and dropped 8.74% in 2024, its largest moves.
• Harmony Biosciences Holdings' Cash & Equivalents stood at $286.9 million in 2022, then grew by 8.64% to $311.7 million in 2023, then surged by 45.35% to $453.0 million in 2024, then soared by 66.11% to $752.5 million in 2025, then fell by 21.67% to $589.4 million in 2026.
• The last three Cash & Equivalents figures came in at $589.4 million (Q1 2026), $752.5 million (Q4 2025), and $647.0 million (Q3 2025), per Business Quant data.